

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for the securities of the Company.



BIOSYSEN LIMITED

生物系統工程有限公司

*(formerly known as “Legend Strategy International Holdings Group Company Limited
枋濬國際集團控股有限公司”)*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1355)

RESULTS OF THE RIGHTS ISSUE ON THE BASIS OF ONE (1) RIGHTS SHARE FOR EVERY TWO (2) EXISTING SHARES HELD ON THE RECORD DATE

References are made to (i) the prospectus of Biosysen Limited (the “**Company**”) dated 4 August 2026 (the “**Prospectus**”) in relation to the Rights Issue of the Company on the basis of one (1) Rights Share for every two (2) existing Shares held on the Record Date at the Subscription Price of HK\$0.068 per Rights Share; (ii) and the announcement of the Company dated 25 August 2026 (the “**Announcement**”) in relation to the results of valid acceptances of the Rights Issue and the number of Unsubscribed Shares subject to the Compensatory Arrangements. Unless the context requires otherwise, capitalised terms used in this announcement shall have the same meanings as those defined in the Prospectus.

RESULTS OF THE RIGHTS ISSUE, THE COMPENSATORY ARRANGEMENTS AND THE PLACING AGREEMENT

As disclosed in the Announcement, as at 4:00 p.m. on Tuesday, 18 August 2026, being the Latest Time for Acceptance, a total of 15 valid acceptances for a total of 340,531,862 Rights Shares had been received, representing approximately 57.09% of the total number of Rights Shares offered under the Rights Issue (the “**Offered Shares**”). Accordingly, the Rights Issue was undersubscribed by 256,000,718 Rights Shares, representing approximately 42.91% of the total number of the Offered Shares, which were subject to the Compensatory Arrangements.

The Company has, pursuant to Rule 7.21(1)(b) of the Listing Rules, made the Compensatory Arrangements by entering into the Placing Agreement with the Placing Agent pursuant to which the Company appointed the Placing Agent and the Placing Agent agreed to act as the placing agent for the Company to procure, on a best-effort basis, to place the Unsubscribed Rights Shares during the Placing Period to independent placees.

The Board wishes to announce that at 4:00 p.m. on Wednesday, 2 September 2026, being the latest time of placing of the Placing Shares by the Placing Agent, 256,000,718 Unsubscribed Rights Shares were successfully placed to not less than six (6) Placees at the price of HK\$0.068 per Share, which is equal to the Subscription Price, under the Placing. Therefore, there is no Net Gain available for distribution to the No Action Shareholders.

All conditions with respect to the Rights Issue and the Placing as set out in the Prospectus have been fulfilled, the Rights Issue and the Placing became unconditional at 4:00 p.m. on Thursday, 3 September 2026.

Based on the results of acceptance of the Rights Issue and the results of the Placing, the Rights Shares to be allotted and issued amounted to 596,532,580 Rights Shares, representing 100% of the total number of Rights Shares available for subscription under the Rights Issue.

To the best of the Directors' knowledge, information and belief after having made all reasonable enquiries, (i) each of the Placees is an Independent Third Party; and (ii) none of the Placees has become a substantial Shareholder immediately upon completion of the Placing.

PROCEEDS FROM THE RIGHTS ISSUE

The gross proceeds from the Rights Issue were approximately HK\$40 million and the net proceeds from the Rights Issue, after deducting the related expenses, were approximately HK\$39 million. As disclosed in the Prospectus, the Company intends to apply the net proceeds from the Rights Issue as follows:

- (i) approximately HK\$13 million, representing approximately 33.3% of the net proceeds, will be applied towards the R&D Projects as follows: (i) approximately HK\$8.5 million for the continuous testing and development of the R&D Projects; and (ii) approximately HK\$4.5 million for staff costs in connection with the R&D Projects;

- (ii) approximately HK\$8 million, representing approximately 20.5% of the net proceeds, will be allocated to sales and marketing expenses in connection with the healthcare and beauty business segment of the Group, the net proceeds will be applied as follows: (i) approximately HK\$5.0 million for the sales and marketing team and key opinion leader expenses; and (ii) approximately HK\$3.0 million for promotion materials, trade shows and exhibition costs. The primary focus of the sales and marketing expenditure will be on promoting the Group's existing healthcare and beauty products. The Group may also utilise part of the budget to raise market awareness of its ongoing R&D Projects and should any of the R&D Projects be successfully developed, to pave the way for the commercialisation of such new products;
- (iii) approximately HK\$6 million, representing approximately 15.4% of the net proceeds, will be allocated to the renovation and upgrading of the Group's hotel properties, including improving accommodation ancillary facilities and implementing staff performance programmes, with a view to enhancing customers' satisfaction and boosting revenue of the Group's accommodation business; and
- (iv) approximately HK\$12 million, representing approximately 30.8% of the net proceeds, will be used for general working capital purposes, including (a) inventories, trade receivables, prepayments and deposits; and (b) day-to-day operating expenses of the Group, which for the year ended 31 December 2025 comprised principally employee benefit expenses of approximately HK\$17,152,000, expenses relating to short-term leases on general office of approximately HK\$2,646,000, legal and professional fees of approximately HK\$2,161,000, utilities of approximately HK\$1,729,000, auditor's remuneration of approximately HK\$935,000 and building management fees of approximately HK\$647,000.

EFFECT OF THE RIGHTS ISSUE ON SHAREHOLDING STRUCTURE OF THE COMPANY

To the best of the Directors' knowledge, information and belief after having made all reasonable enquiries, based on public information available, the shareholding structure of the Company immediately before and after completion of the Rights Issue are as follows:

Shareholders	Immediately before completion of the Rights Issue		Immediately after completion of the Rights Issue	
	<i>Number of Shares</i>	<i>Approximate % (Note 1)</i>	<i>Number of Shares</i>	<i>Approximate % (Note 1)</i>
Mr. Cheung Ching Mo (Note 2)	345,929,020	28.99	518,893,530	28.99
Li Baoshan (Note 3)	93,940,000	7.87	135,440,000	7.57

Shareholders	Immediately before completion of the Rights Issue		Immediately after completion of the Rights Issue	
	<i>Number of Shares</i>	<i>Approximate % (Note 1)</i>	<i>Number of Shares</i>	<i>Approximate % (Note 1)</i>
Kwan Man Cheuk	66,082,000	5.54	69,962,000	3.91
Placees (Note 4)	–	–	214,500,718	11.99
Other public Shareholders	687,114,140	57.60	850,801,492	47.54
Total	<u>1,193,065,160</u>	<u>100.00</u>	<u>1,789,597,740</u>	<u>100.00</u>

Notes:

1. The percentage figures have been subject to rounding adjustments. Any discrepancies between totals and sums of amounts listed herein are due to rounding adjustments.
2. The Shares are registered in the name of Osibao Cosmetics HK. Mr. Cheung Ching Mo, a non-executive Director of the Company, holds the entire issued share capital of CRMT and CRMT effectively holds the entire issued share capital of Osibao Cosmetics HK. Mr. Cheung Ching Mo was therefore deemed to be interested in the Shares in which Osibao Cosmetics HK was interested pursuant to the SFO.
3. 41,500,000 Unsubscribed Rights Shares were placed to Li Baoshan under the Compensatory Arrangements.
4. The total number of Placing Shares is 256,000,718. To avoid double counting of the Placing Shares placed to Li Baoshan as stated in Note 3 above, the total number of Placing Shares stated here excludes those placed to Li Baoshan.

DESPATCH OF SHARE CERTIFICATES FOR THE RIGHTS SHARES

Share certificates for the fully-paid Rights Shares are expected to be posted on Tuesday, 8 September 2026 to those entitled thereto at their registered addresses by ordinary post at their own risks.

COMMENCEMENT OF DEALINGS IN FULLY-PAID RIGHTS SHARES

Dealings in the Rights Shares, in their fully-paid form, are expected to commence on the Stock Exchange on Wednesday, 9 September 2026.

By order of the Board
Biosysen Limited
Lee Tsz Yan
Executive Director

Hong Kong, 7 September 2026

As at the date of this announcement, the Board comprises Ms. Lee Tsz Yan as executive Director; Mr. Cheung Ching Mo and Mr. Hu Xinglong as non-executive Directors; and Mr. Wu Jilin, Mr. Lam Cheung Shing Richard and Mr. So Yin Wai as independent non-executive Directors.